申请人:Congreve Miles Stuart
公开号:US20100152184A1
公开(公告)日:2010-06-17
The invention provides a compound for use in medicine, the compound being a compound of the formula (VI
0
) or a salt, solvate, tautomer or N-oxide thereof:
wherein the bicyclic group:
is selected from the structures C1, C5 and C6:
wherein n is 0, 1, 2 or 3; R
1
is hydrogen, hydroxy, or O—R
z
; R
2a
is hydroxy, methoxy or O—R
z
; provided that at least one of R
1
and R
2a
is O—R
z
; R
z
is L
p
-R
p1
; SO
3
H; a glucuronide residue; a mono-, di- or tripeptide residue; or
L
p
is a bond, C═O, (C═O)O, (C═O)NR
p1
or S(O)
x
NR
p1
; x is 1 or 2; R
p1
is hydrogen or a an optionally substituted C
1-25
hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that R
p1
is not hydrogen when L
p
is a bond, C═O or (C═O)O; and provided also that O—R
z
does not contain an O—O moiety; and excluding compounds wherein R
1
is hydroxy and R
2a
is methoxy; R
p2
and R
p3
are the same or different and each is a group R
p1
; and R
3
, R
4a
, R
8
and R
10
are defined in the claims.
The compounds of formula (VI
0
) are pro-drugs of parent compounds wherein R
1
and/or R
2a
are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.
本发明提供了一种用于药物中的化合物,该化合物是式(VI0)的化合物或其盐、溶剂化物、互变异构体或N-氧化物:其中双环基团:选自结构C1、C5和C6:其中n为0、1、2或3;R1为氢、羟基或O—Rz;R2a为羟基、甲氧基或O—Rz;条件是R1和R2a中至少一个是O—Rz;Rz为Lp-Rp1;SO3H;一个葡萄糖苷酸残基;一个单、二或三肽残基;或Lp为键、C═O、(C═O)O、(C═O)NRp1或S(O)xNRp1;x为1或2;Rp1为氢或一个可选地取代的含0、1或2个碳环和0、1、2、3、4、5或6个碳-碳多重键的C1-25烃基团,条件是当Lp为键、C═O或(C═O)O时,Rp1不是氢;并且还条件是O—Rz不包含O—O部分;并排除R1为羟基且R2a为甲氧基的化合物;Rp2和Rp3相同或不同,且各自为Rp1基团;R3、R4a、R8和R10如权利要求中定义。式(VI0)的化合物是其中R1和/或R2a为羟基的母化合物的前药,其中母化合物具有Hsp90抑制活性。